China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in property holding activities. As of December 31, 2021, the company operated 801 retail pharmacies under the CR Care and Teck Soon Hong brands. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
Revenue of China Resources Pharmaceutical Group Limited (3320.HK)
Revenue in 2023 (TTM): $34.74 B
According to China Resources Pharmaceutical Group Limited's latest financial reports the company's current revenue (TTM) is $34.74 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of China Resources Pharmaceutical Group Limited
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $34.74 B | $5.57 B | $1.98 B | $1.27 B | $495.25 M |
| 2022 | $32.65 B | $5.03 B | $1.99 B | $1.22 B | $449.76 M |
| 2021 | $30.43 B | $4.55 B | $1.53 B | $1.04 B | $395.85 M |
| 2020 | $25.75 B | $4.15 B | $1.6 B | $882.58 M | $357.04 M |
| 2019 | $26.27 B | $4.37 B | $1.62 B | $835.1 M | $422.28 M |
| 2018 | $24.37 B | $4.49 B | $1.75 B | $1.18 B | $518.84 M |
| 2017 | $22.17 B | $3.63 B | $1.38 B | $1.1 B | $447.55 M |
| 2016 | $20.14 B | $3.1 B | $1.28 B | $1.03 B | $362.53 M |
| 2015 | $18.83 B | $2.98 B | $1.18 B | $1.03 B | $366.22 M |
| 2014 | $17.44 B | $2.76 B | $1.07 B | $889.53 M | $339.99 M |
| 2013 | $15.03 B | $2.59 B | $991.94 M | $888.26 M | $339.16 M |